Orphan Drugs' Growth Spurt  

Shows No Sign Of Stopping



Free to download:

It’s free to download, just fill out our form below. Enjoy!

* Required Fields

This e-Book explores the affordability issue, including: 

  • Long-term financing plans
  • Outcome-based pricing models
  • The pharma leaders in orphan drug

With specialty med approvals expanding, the discussion around cost is just getting started. That makes this deep dive on affordability required reading.  Download this free e-Book to stay on the pulse.

The orphan drug market is projected to outpace the rest of the industry.

According to EvaluatePharma, orphan drug sales will grow at a rate of 11% annually, compared to 6.4% growth for the overall pharma sector.

Given the sunny forecast, companies are increasingly eyeing the space. But challenges abound for marketers, namely how to make these high-priced drugs more affordable. It doesn't help that the current administration is framing specialty drugs as the main catalyst behind growth in medical spending.

Fix the following errors: